Skye Bioscience Doses First Patient in Nimacimab Study Skye dosed the first patient in the nimacimab expansion study on Apr 2, 2026, marking an operational milestone; enrollment pace and biomarker data will determine impact.

Skye Bioscience Doses First Patient in Nimacimab Study: Skye dosed the first patient in the nimacimab expansion study on Apr 2, 2026, marking an operational milestone; enrollment pace and biomarker data… 👈 Read full analysis #SkyeBioscience #Nimacimab #ClinicalTrials #Biotechnology #Pharmaceuticals

Halozyme and Skye Bioscience Forge Collaboration to Tackle Obesity with Nimacimab Halozyme and Skye Bioscience have entered a global partnership to develop Nimacimab with ENHANZE® technology, targeting obesity treatment. This collaboration aims to enhance drug delivery efficiency and evaluation of higher doses.

Halozyme and Skye Bioscience Forge Collaboration to Tackle Obesity with Nimacimab #USA #San_Diego #Halozyme #Skye_Bioscience #nimacimab

Skye Bioscience Investors Invited to Join Class Action for Recovery from Losses Attention Skye Bioscience, Inc. shareholders: join a class action to recover losses from misleading statements about the company's lead product. Act now!

Skye Bioscience Investors Invited to Join Class Action for Recovery from Losses #United_States #New_York #Class_Action #Skye_Bioscience #nimacimab

Investors of Skye Bioscience Should Act Now for Possible Class Action Recovery Shareholders of Skye Bioscience Inc. should reach out to The Gross Law Firm regarding a potential class action lawsuit. Act before the deadline.

Investors of Skye Bioscience Should Act Now for Possible Class Action Recovery #United_States #New_York #The_Gross_Law_Firm #Skye_Bioscience #nimacimab

Faruqi & Faruqi, LLP Launches Investigation for Skye Bioscience Investors Faruqi & Faruqi, LLP is investigating claims on behalf of investors of Skye Biosciences, Inc. regarding false statements on drug effectiveness.

Faruqi & Faruqi, LLP Launches Investigation for Skye Bioscience Investors #United_States #New_York #Faruqi_&_Faruqi #nimacimab #SKYE

Berger Montague Investigates Legal Claims for Skye Bioscience Investors After Class Action Announcement Berger Montague PC is initiating an investigation for investors of Skye Bioscience, Inc. following a class action lawsuit claiming misinformation about its product efficacy.

Berger Montague Investigates Legal Claims for Skye Bioscience Investors After Class Action Announcement #United_States #San_Diego #Berger_Montague #Skye_Bioscience #nimacimab

Important Deadline Approaches for Skye Bioscience, Inc. Shareholders in Ongoing Lawsuit Investors of Skye Bioscience, Inc. must act quickly as a deadline for lawsuits looms. If shares over $100,000 were purchased between November 2024 and October 2025, take note.

Important Deadline Approaches for Skye Bioscience, Inc. Shareholders in Ongoing Lawsuit #USA #San_Diego #securities_litigation #Skye_Bioscience #nimacimab

Investors of Skye Bioscience Face Legal Action Over Securities Violations Skye Bioscience, Inc. is facing a lawsuit related to securities law violations. Shareholders are urged to take action before the deadline.

Investors of Skye Bioscience Face Legal Action Over Securities Violations #United_States #New_York #SEC_Lawsuit #Skye_Bioscience #nimacimab

Investors in Skye Bioscience, Inc. Urged to Join Class Action Lawsuit Over Fraud Allegations Investors are encouraged to participate in a class action lawsuit against Skye Bioscience, Inc. due to alleged securities fraud involving misrepresented drug effectiveness.

Investors in Skye Bioscience, Inc. Urged to Join Class Action Lawsuit Over Fraud Allegations #USA #Los_Angeles #Schall_Law_Firm #Skye_Bioscience #nimacimab

Skye Bioscience Investors Face Investigation Following Poor Phase 2a Trial Results Investors of Skye Bioscience, Inc. are being advised by Pomerantz LLP to check for potential securities fraud after recent trial results led to a significant stock drop.

Skye Bioscience Investors Face Investigation Following Poor Phase 2a Trial Results #USA #New_York #Pomerantz_LLP #Skye_Bioscience #nimacimab